60 Degrees Sets October 6 Interim Analysis for Babesiosis Trial, Updates Cash Runway to Early October
SXTP is trading near its 52-week low of $0.897 (8.9% above the low).
Summary
60 Degrees Pharmaceuticals updated its investor deck with a firm October 6, 2026 interim analysis date for its babesiosis trial and confirmed cash runway only through early October 2026.
Key Events · Product Development and Regulatory · SXTP
-
Interim Analysis Set for October 6
The randomized placebo-controlled babesiosis hospital study (NCT06207370) will undergo interim analysis on 10/6/2026, with outcome disclosure before 10/30/2026.
-
Cash Runway Through Early October
The presentation confirms ~$1.0M cash and equivalents at June 30, 2026 and an operating runway only through early October 2026, leaving minimal buffer around the interim analysis.
-
Regulatory Path Outlined
A Q4 2026 pre-sNDA FDA meeting is planned, with earliest feasible sNDA submission April 2027 and potential PDUFA date Q4 2027 under priority review.
-
Babesiosis Market Opportunity Sized
The company estimates the babesiosis treatment opportunity at $180M in WAC value, potentially tripling the ARAKODA asset to $270M combined with malaria prevention.
Analysis · SXTP · Life Sciences
The updated investor presentation discloses a near-term clinical catalyst — the interim analysis of the randomized babesiosis hospital study on October 6, 2026, with results to be disclosed before October 30. That is the first hard date for a data readout that could validate the company's core label-expansion thesis. The presentation also confirms the cash runway extends only to early October 2026, meaning the company is essentially funding the trial through the interim analysis with little margin for delay. The Q4 2026 pre-sNDA FDA meeting and April 2027 earliest sNDA submission provide a regulatory path, but the immediate story is whether the October data supports continued development.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTP was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $0.90 to $8.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.